Accessibility Menu
Immuneering logo

Immuneering

(NASDAQ) IMRX

Current Price$5.05
Market Cap$322.84M
Since IPO (2021)-72%
5 YearN/A
1 Year+47%
1 Month+12%

Immuneering Financials at a Glance

Market Cap

$322.84M

Revenue (TTM)

$0.00

Net Income (TTM)

-$54.44M

EPS (TTM)

-$1.17

P/E Ratio

-4.28

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$5.05

Volume

1,102,004.122

Open

$4.99

Previous Close

$5.05

Daily Range

$4.88 - $5.18

52-Week Range

$2.90 - $10.08

Estimated Earnings Date

Aug 12, 2026

IMRX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuneering

Industry

Biotechnology

Employees

55

CEO

Benjamin J. Zeskind, PhD, MBA

Headquarters

Cambridge, MA 02142, US

IMRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.11%

Return on Capital

-26.71%

Return on Assets

-0.03%

Earnings Yield

-23.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$322.84M

Shares Outstanding

64.70M

Volume

1.10M

Avg. Volume

1.47M

Financials (TTM)

Gross Profit

-$793.21K

Operating Income

-$59.23M

EBITDA

-$58.85M

Operating Cash Flow

-$49.70M

Capital Expenditure

-$213.21K

Free Cash Flow

-$49.91M

Cash & ST Invst.

$156.69M

Total Debt

$3.73B

Immuneering Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$180.48K

N/A

Gross Margin

0.00%

N/A

Market Cap

$322.84M

N/A

Market Cap/Employee

$5.98M

N/A

Employees

54

N/A

Net Income

-$13.46M

+10.5%

EBITDA

-$15.15M

+1.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$156.69M

+336.9%

Total Debt

$3.73B

+91265.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.32B

+88921.7%

Short Term Debt

$413.25M

+117126.4%

Return on Assets

-0.03%

N/A

Return on Invested Capital

-0.03%

N/A

Free Cash Flow

-$18.51M

-31.4%

Operating Cash Flow

-$18.43M

-30.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZURAZura Bio Limited
$5.01-15.17%
ENTAEnanta Pharmaceuticals, Inc.
$14.77+1.30%
TRDAEntrada Therapeutics, Inc.
$7.59+3.13%
FHTXFoghorn Therapeutics Inc.
$5.01+2.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$18.15+0.00%
TAT&T
$20.48-0.01%
NUNu Holdings
$13.39+0.00%
PATHUiPath
$11.55+0.06%

Questions About IMRX

What is the current price of Immuneering?

Immuneering is trading at $5.05 per share.

What is the 52-week range for Immuneering?

Over the past 52 weeks, Immuneering has traded between $2.90 and $10.08.

How much debt does Immuneering have?

As of the most recent reporting period, Immuneering reported total debt of $3.73M.

How much cash does Immuneering have on hand?

Immuneering reported $47.32M in cash and cash equivalents in its most recent financial results.

What is Immuneering’s dividend yield?

Immuneering does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.